anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Self-monitoring is crucial for behavioral weight loss. However, few studies have examined the role of self-monitoring using mixed methods, which may hinder our understanding of its impact.
METHODS: This study examined self-monitoring data from 61 Chinese adults who participated in a 5-week online group intervention for weight loss. Participants reported their baseline Body Mass Index (BMI), weight loss motivation, and engaged in both daily quantitative self-monitoring (e.g., caloric intake, mood, sedentary behavior, etc.) and qualitative self-monitoring (e.g., daily log that summarizes the progress of weight loss). The timeliness of participants' daily self-monitoring data filling was assessed using a scoring rule. One-way repeated measurement ANOVA was employed to analyze the dynamics of each self-monitoring indicator. Correlation and regression analyses were used to reveal the relationship between baseline data, self-monitoring indicators, and weight change. Content analysis was utilized to analyze participants' qualitative self-monitoring data. Participants were categorized into three groups based on their weight loss outcomes, and a chi-square test was used to compare the frequency distribution between these groups.
RESULTS: After the intervention, participants achieved an average weight loss of 2.52 kg (SD = 1.36) and 3.99% (SD = 1.96%) of their initial weight. Daily caloric intake, weight loss satisfaction, frequency of daily log, and the speed of weight loss showed a downward trend, but daily sedentary time gradually increased. Moreover, regression analysis showed that baseline BMI, weight loss motivation, and timeliness of daily filling predicted final weight loss. Qualitative self-monitoring data analysis revealed four categories and nineteen subcategories. A significant difference in the frequency of qualitative data was observed, with the excellent group reporting a greater number of daily logs than expected in all categories and most subcategories, and the moderate and poor groups reporting less than expected in all categories and most subcategories.
CONCLUSION: The self-monitoring data in short-term online group intervention exhibited fluctuations. Participants with higher baseline BMI, higher levels of weight loss motivation, and timely self-monitoring achieved more weight loss. Participants who achieved greater weight loss reported a higher quantity of qualitative self-monitoring data. Practitioners should focus on enhancing dieters' weight loss motivation and promote adherence to self-monitoring practices.
PURPOSE:To obtain an ameliorant for cerebral functions, containing ephedrine as an active ingredient and having cerebral neuron protecting actions and high safety. CONSTITUTION:This ameliorant for the cerebral functions contains ephedrine or its salt (e.g. l-ephedrine) or Ephedra sinica which is a plant containing the ephedrine or its extract as an active ingredient. The ameliorant is useful as a therapeutic agent for cerebral angiopathy for mental, nervous and subjective symptoms, activity disorder in daily living, etc. The ameliorant can be prepared as an oral agent such as a tablet, a capsule, a granule, a fine granule or a powder or a parenteral agent such as an injection or a suppository. The daily dose thereof for an adult is 2.5-25mg (the dose is twice in the case of dl- ephedrine hydrochloride) expressed in terms of U-ephedrine hydrochloride at a time administered 1-3 times in the case of the oral agent and 25-40mg (40mg in the case of dl-ephedrine hydrochloride) at a time in the case of the injection. When the active ingredient is the Ephedra sinica or its extract, the dose for an adult is 1.5-9g as the active ingredient and orally administered in several portions.
Treatment A (Cortisone tbl.) is current treatment, i.e. glucocorticoid and mineralocorticoid replacement according to best clinical judgement. This treatment period will take 6 months.
Each 100 ul actuation contains the colorants plus excipients. A maximum of 48 actuations was permitted in any 24 hour period.
Efficacy for PERSERIS was demonstrated in an 8-week, randomized, double-blind, placebo-controlled study (Study 1, NCT #02109562). The study evaluated the efficacy, safety and tolerability of PERSERIS (90 and 120 mg subcutaneous every 4-weeks) compared with placebo in adults (age 18- to 55-years, inclusive) experiencing acute exacerbations of schizophrenia. Patients were required to have a Positive and Negative Syndrome Scale (PANSS) total score of 80- to 120-inclusive (moderate to severely ill) at the screening visit, occurring 3- to 8-days before the start of double-blind treatment, without an improvement in the PANSS total score of ≥ 20% between screening and the first dosing day. 

At the screening visit, all patients received two doses of 0.25 mg oral risperidone 24-hours apart to establish tolerability. Patients were then placed in an inpatient setting, if not already hospitalized, and tapered off their current oral antipsychotic medication (if they were taking one) over a period of 3- to 8-days. Patients were randomized to receive 2 doses of subcutaneous PERSERIS (90 mg or 120 mg) or placebo 28-days apart (on Day 1 and Day 29). No supplemental oral risperidone was permitted during the study. 

The primary endpoint was the change in PANSS total score from baseline to end of study (Day 57). Both PERSERIS 90 and 120 mg doses demonstrated a statistically significant improvement compared with placebo based on the primary endpoint (Table 8). The results at each scheduled visit are displayed in Figure 14. 

Characteristics of the patient population were balanced across the treatment groups. The mean baseline PANSS total score ranged from 94 to 96 across the groups. Most patients were male (74 to 83% per group), and the mean ages were 40 to 43 in each group. Most patients in this study were black or African American (71 to 75% per group). Of the 354 patients randomized to treatment, 337 were included in the intent-to-treat (ITT) population, and 259 (73%) completed the study. 

Subgroup analyses by gender, age, and race did not suggest any clear evidence of differential responsiveness to PERSERIS. 

Figure 14. Least Square Mean Change from Baseline (+/- Standard Error) in PANSS Total Scores by Days

The secondary efficacy endpoint was defined as the CGI-S score at Day 57. Both PERSERIS treatment groups demonstrated statistically significantly better CGI-S scores versus placebo.
PURPOSE:To improve the age stability of the titled preparation obtained by the polyethylene glycol (PEG) fractionation process and containing less than specific amount of PEG, by adding glucose to the titled preparation. CONSTITUTION:A gamma-globulin solution obtained by PEG (average molecular weight; 3,000-20,000) fractionation process is subjected to e.g. alcohol fractionation, salting-out or treatment with synthetic adsorbent to remove PEG and to obtain a gamma-globulin solution having a PEG concentration of <=0.05% based on protein concentration of 5-20W/V%. The obtained solution is sterilized by conventional filtration process, added with 1-10% of glucose based on 5-20W/V% of protein, and freeze-dried to obtain a dried preparation. The preparation is divided into packaging units each containing 500-1,000mg of gamma-globulin. It is administered by intravenous injection after dissolving in distilled water for injection.
BACKGROUND: Free nipple grafting makes sensory recovery challenging. Permanent decreased sensation to touch and temperature in skin-grafted skin is common. Direct neurotization of the nipple-areolar complex (NAC) graft has been described. However, quantitative data regarding degree of nipple reinnervation possible is unknown. This study aims to quantify and qualify sensation recovery following nerve coaptation to reinnervate the NAC.
METHODS: Patients undergoing mastectomy for gender dysphoria from 2020 to 2022 were offered nerve allograft to restore nipple sensation. A lateral intercostal nerve was selected and coapted to allograft which was embedded beneath the nipple graft. Semmes Weinstein testing was used to assess nipple sensation. Assessments were made at visits <1 year and >1 year from surgery. Filaments used represented normal sensation, minor diminished sensation, diminished sensation, loss of protective sensation, and deep pressure sensation only.
RESULTS: A total of 115 patients elected for direct neurotization. Semmes Weinstein testing was limited to 46 patients representing 46 encounters and 92 nipples in the <1 year group and 24 encounters and 48 nipples in the >1 year group. Of the 92 nipples in the <1 year group, 17 (18.5%) noted return of normal sensation and 37 (40.2%) noted minor diminished or diminished sensation, indicating nerve reinnervation. There were 38 (41%) nipples with loss of protective sensation or deep sensation only. There were 48 nipples included in the >1 year group. Of the 48 nipples, 4 (8.3%) noted normal sensation and 30 (62.5%) noted minor diminished or diminished sensation, indicating nerve reinnervation. For the remaining 14 nipples, 14 (29%) noted loss of protective sensation or deep sensation only.
CONCLUSION: Sensory outcomes in NAC grafts used for reconstruction in patients undergoing double incision mastectomy remain poor. Sensation restoration beyond that expected from full thickness skin grafts can be achieved in the majority of patients with nerve allograft via direct neurotization.
PCT No. PCT/SE94/00244 Sec. 371 Date Sep. 19, 1995 Sec. 102(e) Date Sep. 19, 1995 PCT Filed Mar. 18, 1994 PCT Pub. No. WO94/21286 PCT Pub. Date Sep. 29, 1994A solid pharmaceutical composition for oral administration of small and medium size peptides, particularly vasopressin, oxytocin, and their analogues, comprises the peptide, a protease inhibitor, an enteric coat and a pharmaceutically acceptable carrier containing a buffering agent buffering at a pH of from 3 to 6, preferably about pH 5. A method of manufacture of single doses of the peptide comprises mixing of the ingredients, forming the resulting mixture into spheres smaller than 2 mm, coating the spheres with an enteric coat which is readily soluble in gastric juice of pH 5.0 or higher but not at substantially lower pH, and filling the coated spheres in capsules or incorporating them into tablets, degradable in the stomach. Also disclosed is a method for oral administration to a patient of the single dose.
The first researcher of the article who applied Motivational Interviewing Techniques has a "Motivational Interviewing Techniques Training" certificate. A motivational interview (MI) program based on the telenursing approach was prepared by the researchers based on the literature for the individuals in the experimental group. In this study, the MI procedure includes eight sessions in total, with four sessions of motivational interviews by phone in the first month of the intervention and four sessions of motivational interviews by phone in the next two months for each individual. Pre-tests were collected in the first month. Afterwards, MI intervention was applied for three months. This intervention was applied to the experimental group in addition to the routine care provided by the hospital. MI application took an average of 45-60 minutes via phone call.
An aberrant healing reaction to cutaneous injury or inflammation that spreads outside the original wound's boundaries causes keloidal scars. We present the case of a sixty-year-old male patient who initially came with complaints of respiratory system but had spontaneous lesions over his body for 50 years which remained undiagnosed. It was confirmed on histological examination to be keloids. The patient was treated with intralesional triamcinolone acetonide 40 mg plus an injection of lignocaine hydrochloride 2% in the ratio of 1:1 which provided him with a significant reduction in scar appearance over one month and thereby reducing his psychological burden. It is uncommon for spontaneous keloid scars to occur without any prior trauma or surgical intervention. Also, it details a manifestation of spontaneous keloid scars that manifest as numerous sizable lesions at various body locations. This study provides evidence in favor of such spontaneous appearance of keloid scars.
INTRODUCTION: This research endeavors to investigate the phenomenon of intraneural spread across distinct locations: subcircumneurium, extrafascicular intraneural, intrafascicular intraneural, and intraperineurium after deliberate intraneural injections across five mammalian species. The study also aims to propose determinants influencing this spread. Furthermore, the investigation strives to ascertain the optimal animal species and needle configuration for extrapolating intraneural injection outcomes to human contexts.
METHODS: This study examined 60 sciatic nerves from 30 fresh and untreated cadavers of rats, rabbits, dogs, pigs, and sheep. The specimens were organized into five groups, each comprising an equal number of nerves. Histological assessments were performed on 30 nerves, involving fascicle metrics. The remaining 30 nerves underwent intentional intraneural injections, facilitated by 19G and 23G needles under ultrasound and direct visualization guidance.Heparinized erythrocytes combined with a methylene blue solution were used as a marker to analyze the extent and patterns of intraneural spread. Needle orifice measurements were obtained, and these data were overlaid onto images of both nerves and needles. This enabled a comparative evaluation of sizes and an assessment of marker diffusion.
RESULTS: The findings indicated that sciatic nerves in rats, rabbits, and dogs were oligofascicular, characterized by larger fascicles, whereas pigs and sheep exhibited polyfascicular nerves comprised of numerous smaller fascicles. Fascicular diameters were variable across species, with dogs presenting the largest measurements. While intraneural spread was observed and documented, intrafascicular marker spreading was rare, occurring only in one rabbit specimen. Needle orifice attributes were scrutinized and visually depicted.
CONCLUSIONS: Despite the formidable challenges associated with the practical realization of intrafascicular injection, the utilization of animal models possessing monofascicular or oligofascicular nerves, such as rats, rabbits, and dogs, in conjunction with needles featuring aperture dimensions surpassing those of the fascicles, likely contributes to the compromised reliability of investigations into intraneural injection outcomes.
Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral colchicine 0.6 mg twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
Ertapenem 1 g x 1 for two days i.v. followed by p.o. levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 5 days, duration of treatment one week.
BACKGROUND: Obesity is a common disease with a higher prevalence among African Americans. Obesity alters cellular function in many tissues, including skeletal muscle, and is a risk factor for many life-threatening diseases, including cardiovascular disease and diabetes. The similarities and differences in molecular mechanisms that may explain ethnic disparities in obesity between African and European ancestry individuals have not been studied.
METHODS: In this study, data from transcriptome-wide analyses on skeletal muscle tissues from well-powered human cohorts were used to compare genes and biological pathways affected by obesity in European and African ancestry populations. Data on obesity-induced differentially expressed transcripts and GWAS-identified SNPs were integrated to prioritize target genes for obesity-associated genetic variants.
RESULTS: Linear regression analysis in the FUSION (European, N = 301) and AAGMEx (African American, N = 256) cohorts identified a total of 2569 body mass index (BMI)-associated transcripts (q < 0.05), of which 970 genes (at p < 0.05) are associated in both cohorts, and the majority showed the same direction of effect on BMI. Biological pathway analyses, including over-representation and gene-set enrichment analyses, identified enrichment of protein synthesis pathways (e.g., ribosomal function) and the ceramide signaling pathway in both cohorts among BMI-associated down- and up-regulated transcripts, respectively. A comparison using the IPA-tool suggested the activation of inflammation pathways only in Europeans with obesity. Interestingly, these analyses suggested repression of the mitochondrial oxidative phosphorylation pathway in Europeans but showed its activation in African Americans. Integration of SNP-to-Gene analyses-predicted target genes for obesity-associated genetic variants (GWAS-identified SNPs) and BMI-associated transcripts suggested that these SNPs might cause obesity by altering the expression of 316 critical target genes (e.g., GRB14) in the muscle.
CONCLUSIONS: This study provides a replication of obesity-associated transcripts and biological pathways in skeletal muscle across ethnicities, but also identifies obesity-associated processes unique in either African or European ancestry populations.
Background: As it is known, many negative situations occur in CKD patients on hemodialysis. One of these is the problems seen in the vascular access. The prevention and management of vascular access complications may benefit from exercise The purpose of this study is to investigate the effect of exercise on the vessel diameter in HD patients.

Methods: Present study we were included 100 hemodialysis patients between the ages of 18-65.Participants were randomly divided into two groups: the exercise group and the control group. The exercise group performed moderate-intensity aerobic exercise on a stationary bicycle ergometer for 30 minutes during hemodialysis sessions, three days a week over 12 weeks. Additionally, the exercise group engaged in walking exercise for 30 minutes, three days a week outside of hemodialysis sessions, maintaining the heart rate between 50-60%. The exercise group also performed isolated exercises to expand wrist vessels, including wrist and elbow flexion, extension, and rotation, repeated 10 times, 2-3 days a week outside of hemodialysis sessions. And the vessel diameters of patients were measured by ultrasound at the beginning and after 12 weeks.
ADRC treatment group will receive ADRCs yielded from processing of lipoaspirate by a fluoroscopic-guided injection into the affected segment. The segment will consist of 2 joints per level and up to two levels (no more than 4 joints) injected during the procedure.
479,735. Electro-medical apparatus. SIEBS, S. July 5, 1937, No. 18611. Convention date, July 8, 1936. [Class 81 (ii)] An electrode for short wave treatment of the face comprises a strip a, of flexible metal such as aluminium, positioned over the centre line of the face and having branch strips c . . . . h and m which extend over the forehead, cheeks, and chin and are interlocked at their ends to form a rigid structure, the strips h having further branches i, k. The strips are lined with non-conducting material b such as felt or sponge rubber. The parts a<1>, a<2>, of strip a are longer than required and are looped as shown to adjust the electrode to the size of the fan. Current is supplied at p. The strip a may be extended as at a<3> and may have branches n, o, with lateral extensions for treatment of the neck.
From weeks 1-4, participants will consume 150mg daily of a Geranylgeraniol (GG). For weeks 5-8, the dose will be escalated as participants will consume 300mg daily of GG.
The invention belongs to the technical field of biological medicines, and particularly relates to application of MOF in liver cancer treatment. A liver cancer biomarker, wherein the biomarker is MOF gene/protein, and the use of the MOF gene/protein in the preparation of a kit for detecting liver cancer. Application of MOF or MOF small molecule agonist in preparing medicine and pharmaceutical composition for preventing or treating liver cancer. Experiments prove that the MOF can inhibit growth and invasion and metastasis of liver cancer of liver cells, and the MOF inhibits polyubiquitination degradation of estrogen receptors through acetylation of the 266 th, 268 th and 299 th lysines of the estrogen receptors, so that stability of estrogen receptor proteins is maintained. The MOF can inhibit liver cell liver cancer and prepare an MOF small molecular agonist so as to achieve the function of treating clinical liver cell cancer. The MOF plays a role in inhibiting cancer progression in the process of cancer occurrence and development, the expression of the MOF is down-regulated in most tissues of patients with liver cancer, and the MOF can promote the expression of the MOF to effectively inhibit liver cancer. The invention provides a new idea and a new target spot for treating liver cancer.
PURPOSE: A pharmaceutical composition containing novel polymorphism of prasugrel hydrogensulfate is provided to prevent and treat ischemic diseases. CONSTITUTION: A polymorphism of prasugrel hydrogensulfate of chemical formula 1 has 2 theta diffraction peak at 8.3+/-0.2, 12.0+/-0.2, 12.4+/-0.2, 19.1+/-0.2, 19.5+/-0.2, 22.6+/-0.2, 23.2+/-0.2 or 23.8+/-0.2 in X-ray diffraction analysis irradiated by Cu-K alpha. In chemical formula 1, Ac is acetyl group. The polymorphism of prasugrel hydrogensulfate is prepared by contacting prasugrel with sulfuric acid in inactive organic solvent. The inactive inorganic solvent is ketones, esters, alcohols of 1-6 carbon atoms, ethers, or nitriles. A pharmaceutical composition for preventing and treating ischemic diseases contains the polymorphism of prasugrel hydrogensulfate and pharmaceutically acceptable carrier, diluent, or excipient.
A process is disclosed for the manufacture of an excipient useful for the controlled release of an active agent. In this process, a starting material consisting of starch or high amylose starch is subjected to a gelatinization in an aqueous medium. When the starting material consists of starch having an amylose content of less than 50 % by weight, the gelatinized material is subjected to an enzymatic debranching treatment so as to obtain a gelatinized debranched starch having a short amylose chain content of at least 50 % by weight. When the starting material consists of starch having an amylose content of at least 50 % by weight or of a high amylose starch having an amylose content up to 80 % by weight, the gelatinized material is optionally subjected to an enzymatic debranching treatment so as to obtain a gelatinized debranched starch having a short amylose chain content of 20 % to 50 % by weight. The so obtained gelatinized and optionally debranched starch is further subjected to a thermal dehydration in order to obtain the requested excipient in form of a powder. Also disclosed is a dosage administration form for the sustained release of one or more active agents in the form of a powder. This form which is preferably a tablet, comprises the active agent(s) in admixture with the above excipient in such an amount as to achieve the requested sustained release.